Summary
Apomorphine (0.05 mg/kg intravenously) was given to conscious dogs, and gastrin levels were measured in peripheral venous blood with a radioimmunoassay. Apomorphine induced an increase of gastrin levels which peaked at 5 min. The peripheral dopamine D-2/DA2 receptor antagonist domperidone (0.2 mg/kg), but not halopemide (0.1–1 mg/kg) nor the D-1 /DA1 receptor antagonist SCH 23390 (0.1 mg/kg), blocked the gastrin response to apomorphine. Both domperidone and halopemide, but not SCH 23 390, blocked the Apomorphine-induced vomiting. These results suggest that apomorphine increases gastrin levels by an action at D-2/DA2 receptors, which are situated outside the blood brain barrier and differ from the receptor inducing the vomiting.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Borison HL, Wang SC (1953) Physiology and pharmacology of vomiting. Pharmacol Rev 5:193–230
Brown GM, Verhaegan H, Van Wimersma Greidanus TB, Brugmans J (1981) Endocrine effects of domperidone: a peripheral dopamine blocking agent. Clin Endocrinol 15:275–282
Caldara R, Ferrari C, Romussi M, Bierti L, Gandini S, Curtarelli G (1978) Effect of dopamine infusion on gastric and pancreatic secretion and on gastrin release in man. Gut 19:724–728
Caldara R, Ferrari C, Barbieri C, Romussi M (1980) Effect of four dopamine receptor antagonists on gastrin secretion in healthy subjects. Scand J Gastroenterol 15:481–484
Christensen NJ, Bransborg O (1974) Dopamine in human gastric juice determined by a sensitive double-isotope-derivative technique. Scand J Clin Lab Invest 34:315–320
Costall B, Naylor RJ (1980) Assessment of the test procedures used to analyse neuroleptic action. Rev Pure Appl Pharmacol Sci 1:3–83
Ennis C, Cox B (1980) The dopamine receptor antagonist domperidone is also a competitive antagonist at α1-adrenoceptors. J Pharm Pharmacol 32:434–435
Farah JM, Demarest KT, Moore KE (1983) A comparison of domperidone and haloperidol effects on different dopaminergic neurons in the rat brain. Life Sci 33:1561–1566
Goiny M, Uvnäs-Moberg, Cekan S (1986) Bromocriptine and apomorphine stimulation of cortisol secretion in conscious dogs; evidence for a stimulatory site located outside the blood brain barrier. Psychopharmacology 89:108–112
Goiny M, Uvnäs-Moberg K (1986) Effects of dopaminomimetics on the secretion of VIP-like immunoreactivity in conscious dogs. Peptides Suppl 1:221–224
Goldberg LI, Kohli JD (1979) Peripheral pre- and post-synaptic dopamine receptors: are they different from dopamine receptors in the central nervous system? Commun Psychopharmacol 3:447–456
Goldberg LI, Kohli JD, Glock D (1984) Complete separation of peripheral DA1 and DA2 receptors by selective antagonists. Clin Neuropharmacol 7:802–803
Herrera-Marschitz M, Ungerstedt U (1985) Effect of dopamine D-1 antagonist SCH 23 390 on rotational behaviour induced by apomorphine and pergolide in 6-hydroxy-dopamine denervated rats. Eur J Pharmacol 109:349–354
Hilditch A, Drew GM, Naylor RJ (1984) SCH 23390 is a very potent and selective antagonist at vascular dopamine receptors. Eur J Pharmacol 97:333–334
Hyttel J (1983) SCH 23 390 — the first selective dopamine D-1 antagonist. Eur J Pharmacol 91:153–154
Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J Pharmacol Exp Ther 226:462–468
Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277:93–96
Kohli JD, Glock D, Goldberg LI (1983) Selective DA2 versus DA1 antagonist activity of domperidone in the periphery. Eur J Pharmacol 89:137–141
Laduron PM, Leysen JE (1979) Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol 28:2161–2165
Lam SK, Lay CL (1976) Inhibition of sulpiride on the cephalic phase of gastric acid and gastrin secretion in duodenal ulcer patients. Scand J Gastroenterol 11:27–31
Leysen JE, Gommeren W, Laduron PM (1978) Spiperone: a ligand of choice for neuroleptic receptors. Biochem Pharmacol 27:307–316
Loonen AJM, Van Wijngaarden I, Janssen PAJ, Soudijn W (1978) Regional localisation of halopemide, a new psychotropic agent, in the rat brain. Eur J Pharmacol 50:403–408
Masci E, Caldara R, Testoni PA, Guslandi M, Cambielli M, Passaretti S, Tittobello A (1984) Lack of effect of domperidone on gastrin release: evidence for a peripheral activity of the drug. Br J Clin Pharmacol 17: 588–590
Nilsson G (1975) Increase plasma gastrin levels in connection with inhibition of gastric acid response to sham feeding following bulbar perfusion with acid in dogs. Scand J Gastroenterol 10:273–277
Orloff LA, Orloff MS, Bunnett NW, Walsh JH (1985) Dopamine and norepinephrine in the alimentary tract changes after chemical sympathectomy and surgical vagotomy. Life Sci 36:1625–1631
Rehfeld JF (1976) Disturbed islet cell function related to endogenous gastrin release: studies on insulin secretion and glucose tolerance in pernicious anemia. J Clin Invest 58:41–49
Sahyoun HA, Costall B, Naylor RJ (1982) On the ability of domperidone to selectively inhibit catecholamine-induced relaxation of circular smooth muscle of guinea-pig stomach. J Pharm Pharmacol 34:27–33
Schrumpf E, Linnestad P (1982) Effect of cholinergic, adrenergic, and dopaminergic blockade on gastrin secretion in healthy subjects. Scand J Gastroenterol 17:29–31
Schuurkes JAJ, Van Nueten JM (1981) Effects of dopamine and its antagonist domperidone cannot be explained by an effect on α1-adrenergic receptors. Arch Int Pharmacodyn 250:3245–3247
Stadil F, Rehfeld JF (1973) Determination of gastrin in serum: An evaluation of the reliability of a radioimmunoassay. Scand J Gastroenterol 8:101–112
Thompson JC, Reeder DD, Bunchman HH, Becker HD, Brandt EN (1972) Effect of secretin on circulating gastrin. Ann Surg 176:384–393
Uvnäs-Wallensten K, Lundberg JM, Efendic S (1978) Dopaminergic control of antral gastrin and somatostatin release. Acta Physiol Scand 103:343–345
Uvnäs-Wallensten K, Goiny M (1981) Effect of apomorphine on peripheral venous gastrin and insulin levels in conscious dogs. Acta Physiol Scand 112:155–160
Van Nueten JM, Schuurkes JAJ (1984) Studies on the role of dopamine and dopamine blockers in gastrointestinal motility. Scand J Gastroenterol 19 (Suppl 96):89–99
Willems JL, Buylaert WA, Lefebvre RA, Bogaert MG (1985) Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system. Pharmacol Rev 37:165–216
Author information
Authors and Affiliations
Additional information
Send offprint requests to M. Goiny at the above address
Rights and permissions
About this article
Cite this article
Goiny, M., Uvnäs-Moberg, K. Effects of dopamine receptor antagonists on gastrin and vomiting responses to apomorphine. Naunyn-Schmiedeberg's Arch Pharmacol 336, 16–19 (1987). https://doi.org/10.1007/BF00177745
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00177745